LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akcijų sąrašas・Lisata Therapeutics

L
Lisata Therapeutics

Uždarymo kaina

2.02 0.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.02

Max

2.02

Pagrindiniai rodikliai
By Trading Economics
Darbuotojai	26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.6M 15M
Ankstesnė atidarymo kaina	1.52
Ankstesnė uždarymo kaina	2.02

Lisata Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-14 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025-12-14 23:36; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-12-14 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025-12-14 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025-12-14 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Acquire Remaining 64% of Alta Copper

2025-12-14 17:00; UTC

Uždarbis

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025-12-14 08:30; UTC

Įsigijimai, susijungimai, perėmimai

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 07:00; UTC

Įsigijimai, susijungimai, perėmimai

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Akcijų palyginimas

Kainos pokytis

Lisata Therapeutics Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Lisata Therapeutics akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.